Keros Therapeutics Inc expected to post a loss of $1.13 a share - Earnings Preview

Keros Therapeutics

01/08/2025 12:35

Keros Therapeutics Inc KROS.OQ KROS.O is expected to  show a rise in quarterly revenue when it reports  results on August 5 (estimated) for the period ending June 30 2025

The Lexington Massachusetts-based  company is expected to report a 7,377.0% increase in revenue to $2.767 million from $37 thousand a year ago, according to the mean estimate from 8 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Keros Therapeutics Inc is for a loss of $1.13 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Keros Therapeutics Inc is $25.00, about 42.7% above its last closing price of $14.32

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.15
-0.24
3.62
Beat
1,589.7
Dec. 31 2025
-0.73
-0.98
-1.14
Missed
-16
Sep. 30 2024
-1.26
-1.28
-1.41
Missed
-10.2​
Jun. 30 2024
-1.23
-1.23
-1.25
Missed
-1.5
​​Mar. 31 2024
-1.30
-1.35
-1.21
Beat
10.2
Dec. 31 2023
-1.35
-1.37
-1.34
Beat
2.5​
Sep. 30 2023
-1.34
-1.35
-1.33
Beat
1.3
Jun. 30 2023
-1.33
-1.34
-1.27
Beat
5.1

This summary was machine generated August 1 at 11:35 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)